Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis
Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis
复制标题
DOI：
10.1080/14397595.2018.1510565
复制
发表时间：
2019-07-04
影响因子：
2.2
通讯作者：
Mimori, Tsuneyo
中科院分区：
文献类型：
--
作者：
Torii, Mie;Hashimoto, Motomu;Mimori, Tsuneyo
目的：肌肉减少症的特征是肌肉力量和质量的损失，导致福尔斯和不良的健康结果。我们的目的是确定类风湿性关节炎（RA）患者中肌肉减少症的患病率，并确定这些患者中与肌肉减少症相关的因素。方法：对388名连续的女性类风湿关节炎患者进行横断面研究，评估肌肉质量和力量以及步行速度。评估了前一年持续的福尔斯和骨折。使用逻辑回归分析评估肌肉减少症与RA特征、福尔斯和骨折之间的关联。结果：肌肉减少症的患病率为37.1%（14.7%为重度肌肉减少症; 22.4%为肌肉减少症），其中49.0%为低肌肉质量。伴有肌肉减少症的患者的福尔斯、骨折和骨密度降低的发生率高于不伴有肌肉减少症的患者。年龄、RA病程、Steinbrocker分期、高迷你营养评估简表评分和使用生物疾病缓解抗风湿药物（bDMARDs）是与肌肉减少症相关的独立因素。结论：我们证实，肌肉减少症的发展与RA患者的显着比例。年龄、病程延长、关节破坏和营养不良与肌肉减少症呈正相关，与bDMARDs的使用呈负相关。
Objectives: Sarcopenia is characterized by loss of muscle strength and mass, leading to falls and adverse health outcomes. Our aim was to determine the prevalence of sarcopenia in patients with rheumatoid arthritis (RA) and to identify factors associated with sarcopenia in these patients. Methods: A cross-sectional study of 388 consecutive women with RA was conducted, assessing muscle mass and strength, and walking speed. Falls and bone fractures sustained over the prior year were evaluated. The association between sarcopenia and RA characteristics, falls, and bone fractures was evaluated using logistic regression analyses. Results: The prevalence of sarcopenia was 37.1% (14.7%, severe sarcopenia; 22.4%, sarcopenia), with 49.0% classified as having low muscle mass. The incidence of falls, fractures, and lower bone mineral density was higher in patients with than without sarcopenia. Age, RA duration, Steinbrocker's stage, the high Mini-Nutritional Assessment-Short Form score and the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) were independent factors associated with sarcopenia. Conclusion: We confirmed that sarcopenia develops in a significant proportion of patients with RA. Age, longer disease duration, joint destruction and malnutrition were positively associated with sarcopenia, with the use of bDMARDs being negatively associated.